Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Imipenem

FDA-approved product (powder, intravenous).

Registered studies
50+
Lab records
505
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Imipenem
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Endocarditis
  • Infection
  • Pneumonia
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH51

Repurposing investigation

Imipenem is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae96.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 44 of 77 lab records
  • E. coli: measured active in 86 of 94 lab records
  • K. pneumoniae: measured active in 247 of 334 lab records
Open Imipenem in ChEMBL Registered studies below
Show the latest 150 of 505 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Imipenem with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria

    NCT07524920 · start 2026-04-01

    Registered record
    Registry ID
    NCT07524920
    Conditions
    MDR Bacteria
    Interventions
    "Imipenem/cilastatin" and "Tigecycline"; "colistin" and "meropenem"
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-04-01
    Completion
    2026-09-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMDR Bacteria
    Intervention"Imipenem/cilastatin" and "Tigecycline"; "colistin" and "meropenem"
    PhasePhase 2
    Registry statusNot yet recruiting

  • Percutaneous Transcatheter Genicular Embolization in Osteoarthritis

    NCT07361198 · start 2026-02-02

    Registered record
    Registry ID
    NCT07361198
    Conditions
    Osteoarthritic Knee Pain; Osteo Arthritis of the Knee; Osteoarthitis
    Interventions
    genicular artery embolisation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-02-02
    Completion
    2029-12-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarthritic Knee Pain; Osteo Arthritis of the Knee; Osteoarthitis
    Interventiongenicular artery embolisation
    PhaseNot applicable
    Registry statusRecruiting

  • The Effect of Rifabutin in Mycobacterium Abscessus With Inducible Clarithromycin Resistance

    NCT07514364 · start 2026-01-01

    Registered record
    Registry ID
    NCT07514364
    Conditions
    Mycobacterium Abscessus Lung Disease
    Interventions
    Rifabutin; No Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-01-01
    Completion
    2026-06-18
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Abscessus Lung Disease
    InterventionRifabutin; No Rifabutin
    PhasePhase 4
    Registry statusRecruiting

  • Antimicrobial Resistance in Hospitals From Meta, Colombia

    NCT06044272 · start 2023-09-01

    Registered record
    Registry ID
    NCT06044272
    Conditions
    Increased Drug Resistance
    Interventions
    Factors associated
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-09-01
    Completion
    2024-06-30
    Enrolment
    10,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIncreased Drug Resistance
    InterventionFactors associated
    PhaseNot recorded
    Registry statusCompleted

  • Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy

    NCT05925309 · start 2023-07-01

    Registered record
    Registry ID
    NCT05925309
    Conditions
    Biliary Atresia; Cholangitis; Anti-Bacterial Agents
    Interventions
    Basic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem; Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-07-01
    Completion
    2029-12-31
    Enrolment
    356

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Atresia; Cholangitis; Anti-Bacterial Agents
    InterventionBasic treatment: sulperazone + ursodeoxycholic acid + compound glycyrrhizin + methylprednisolone + vitamin AD , D , E , K + imipenem or meropenem; Prophylactic oral antibiotics: compound sulfamethoxazole tablet (SMZ/TMP) + cefaclor
    PhaseNot applicable
    Registry statusRecruiting

  • Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

    NCT05887908 · start 2023-05-23

    Registered record
    Registry ID
    NCT05887908
    Conditions
    Complicated Urinary Tract Infection; Acute Pyelonephritis; cUTI; AP
    Interventions
    co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam; imipenem/cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-05-23
    Completion
    2024-11-26
    Enrolment
    614

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection; Acute Pyelonephritis; cUTI; AP
    Interventionco-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam; imipenem/cilastatin
    PhasePhase 3
    Registry statusCompleted

  • Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

    NCT05561764 · start 2023-01-03

    Registered record
    Registry ID
    NCT05561764
    Conditions
    Cystic Fibrosis; Pneumonia, Bacterial
    Interventions
    Imipenem/Cilastatin/Relebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2023-01-03
    Completion
    2024-12-11
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Pneumonia, Bacterial
    InterventionImipenem/Cilastatin/Relebactam
    PhasePhase 4
    Registry statusTerminated

  • Longitudinal and Cross-sectional Analysis of Pulmonary Microbiota in Lung Transplant Recipients Infected With Nocardia

    NCT06594133 · start 2023-01-01

    Registered record
    Registry ID
    NCT06594133
    Conditions
    Nocardia Infections; Lung Transplantation
    Interventions
    Antibiotic Treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-01-01
    Completion
    2024-09-01
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNocardia Infections; Lung Transplantation
    InterventionAntibiotic Treatment
    PhaseNot recorded
    Registry statusCompleted

  • Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)

    NCT05204563 · start 2022-07-31

    Registered record
    Registry ID
    NCT05204563
    Conditions
    Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
    Interventions
    Combination of Imipenem/Cilastatin and XNW4107; Imipenem/Cilastatin/Relebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-07-31
    Completion
    2024-09-29
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
    InterventionCombination of Imipenem/Cilastatin and XNW4107; Imipenem/Cilastatin/Relebactam
    PhasePhase 3
    Registry statusCompleted

  • Phenotypic Profile and Molecular Mechanism of Resistance in Carbapenemase-producing Enterobacterales and Pseudomonas Aeruginosa Isolates From Brazilian Hospitals: Implications for the Introduction of IMIPENEM-RELEBACTAM

    NCT05285046 · start 2022-04-01

    Registered record
    Registry ID
    NCT05285046
    Conditions
    Bacterial Infections; Antibiotic Resistant Infection
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-04-01
    Completion
    2023-02-28
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections; Antibiotic Resistant Infection
    InterventionNo intervention
    PhaseNot recorded
    Registry statusUnknown

  • Use of New Antibiotics in Sweden

    NCT05048693 · start 2021-11-01

    Registered record
    Registry ID
    NCT05048693
    Conditions
    Multi-antibiotic Resistance
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-11-01
    Completion
    2023-12-30
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-antibiotic Resistance
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

    NCT04785924 · start 2021-06-07

    Registered record
    Registry ID
    NCT04785924
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection
    Interventions
    Imipenem+Relebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-06-07
    Completion
    2023-01-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection
    InterventionImipenem+Relebactam
    PhasePhase 4
    Registry statusWithdrawn

  • Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

    NCT04802863 · start 2021-03-25

    Registered record
    Registry ID
    NCT04802863
    Conditions
    Bacterial Infections
    Interventions
    XNW4107, Imipenem/Cilastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-25
    Completion
    2021-09-30
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionXNW4107, Imipenem/Cilastatin
    PhasePhase 1
    Registry statusCompleted

  • To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

    NCT04801043 · start 2021-03-02

    Registered record
    Registry ID
    NCT04801043
    Conditions
    Bacterial Infections
    Interventions
    XNW4107; Imipenem/Cilastatin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-02
    Completion
    2022-01-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionXNW4107; Imipenem/Cilastatin; placebo
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

    NCT04482569 · start 2020-07-10

    Registered record
    Registry ID
    NCT04482569
    Conditions
    Bacterial Infections
    Interventions
    XNW4107
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-07-10
    Completion
    2021-09-30
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections
    InterventionXNW4107
    PhasePhase 1
    Registry statusCompleted